for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Catalent Inc

CTLT.N

Latest Trade

49.20USD

Change

0.86(+1.78%)

Volume

203,758

Today's Range

48.57

 - 

49.29

52 Week Range

29.26

 - 

58.38

As of on the New York Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
48.34
Open
48.57
Volume
203,758
3M AVG Volume
15.89
Today's High
49.29
Today's Low
48.57
52 Week High
58.38
52 Week Low
29.26
Shares Out (MIL)
146.26
Market Cap (MIL)
7,070.03
Forward P/E
24.43
Dividend (Yield %)
--

Next Event

Catalent Inc Annual Shareholders Meeting

Latest Developments

More

Acura Pharmaceuticals Says Co Engaged Catalent Pharma Solutions To Initiate Manufacturing Scale-Up Of LTX-03 Tablets

Catalent Biologics Announces Agreement To Provide Production For Spinal Muscular Atrophy

Catalent Extends Global Commercial Spray Drying Capabilities In Europe

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Catalent Inc

Catalent, Inc. provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. Its segments include Softgel Technologies, Drug Delivery Solutions and Clinical Supply Services. The Softgel Technologies segment is engaged in the formulation, development and manufacturing of prescription and consumer health soft capsules or softgels. The Drug Delivery Solutions segment is engaged in the formulation, development and manufacturing of prescription and consumer and animal health products; blow-fill seal unit dose manufacturing; biologic cell line development; analytical and bioanalytical development, and testing services. The Clinical Supply Services segment is engaged in manufacturing, packaging, labeling, storage, distribution and inventory management for clinical trials of drugs and biologics for patient kits; FastChain clinical supply service; clinical e-solutions and informatics, and global comparator sourcing services.

Industry

Biotechnology & Drugs

Contact Info

14 Schoolhouse Rd

+1.732.5376200

https://www.catalent.com/

Executive Leadership

John R. Chiminski

Chairman of the Board, Chief Executive Officer

Alessandro Maselli

President, Chief Operating Officer

Matthew M. Walsh

Chief Financial Officer, Executive Vice President

Wetteny Joseph

Chief Financial Officer, Senior Vice President

Aristippos Gennadios

President - Softgel Technologies

Key Stats

1.67 mean rating - 9 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

2.1K

2018

2.5K

2019

2.5K

2020(E)

2.8K
EPS (USD)

2017

1.460

2018

1.750

2019

1.920

2020(E)

1.979
Price To Earnings (TTM)
51.85
Price To Sales (TTM)
2.81
Price To Book (MRQ)
4.19
Price To Cash Flow (TTM)
19.32
Total Debt To Equity (MRQ)
129.33
LT Debt To Equity (MRQ)
125.99
Return on Investment (TTM)
2.90
Return on Equity (TTM)
2.56

Latest News

Latest News

BRIEF-Catalent Biologics Announces Agreement To Provide Production For Spinal Muscular Atrophy

* CATALENT INC. - CATALENT ANNOUNCES AGREEMENT TO PROVIDE PRODUCTION FOR SPINAL MUSCULAR ATROPHY

Catalent seeks slice of gene therapy market with Paragon buy

Contract drugmaker Catalent Inc said on Monday it would buy privately held Paragon Bioservices Inc for $1.2 billion (916.4 million pounds) in cash, bolstering its capabilities to make gene therapy drugs for its biotech clients.

Catalent to buy Paragon Bioservices for $1.2 bln

Catalent Inc said on Monday it would buy privately held gene therapy-focused Paragon Bioservices Inc in an all-cash deal for $1.2 billion.

Catalent to buy Paragon Bioservices for $1.2 billion: WSJ

Drug developer Catalent Inc has agreed to buy privately held, gene-therapy focused Paragon Bioservices Inc for $1.2 billion, the Wall Street Journal reported on Sunday, citing people familiar with the matter.

Catalent to buy Paragon Bioservices for $1.2 bln -WSJ

Drug developer Catalent Inc has agreed to buy privately held Paragon Bioservices Inc for $1.2 billion, the Wall Street Journal reported on Sunday, citing people familiar with the matter.

Catalent to buy Juniper Pharmaceuticals for $11.50 per share

U.S. drug contract manufacturer Catalent Inc <CTLT.N> said on Tuesday it will buy Juniper Pharmaceuticals Inc <JNP.O> for $11.50 per share in cash.

BRIEF-Catalent Announces Changes To Its Board Of Directors

* CATALENT - ANNOUNCED ADDITION OF 3 NEW MEMBERS TO BOARD AND RETIREMENT OF BOARD MEMBER JAMES QUELLA

BRIEF-Catalent Posts Q2 Loss Per Share $0.16

* QTRLY REVENUE OF $606.3 MILLION INCREASED 25% AS-REPORTED, OR 22 PCT IN CONSTANT CURRENCY FROM PRIOR-YEAR PERIOD

BRIEF-Catalent Q1 earnings per share $0.03

* Q1 earnings per share view $0.17 -- Thomson Reuters I/B/E/S

BRIEF-Catalent completes repricing and extension of credit agreement

* Catalent completes repricing and extension of credit agreement Source text for Eikon: Further company coverage:

BRIEF-Catalent announces pricing of private offering of senior unsecured notes due 2026

* Catalent announces pricing of private offering of senior unsecured notes due 2026

BRIEF-Catalent launches private offering of $450 mln of senior unsecured notes due 2026

* Catalent announces launch of private offering of $450 million of senior unsecured notes due 2026

BRIEF-Catalent Inc announces pricing of public offering

* Catalent Inc announces pricing of public offering of common stock to fund part of its acquisition of Cook Pharmica

BRIEF-Catalent announces public offering of common stock to fund part of its acquisition of Cook Pharmica

* Catalent Inc announces public offering of common stock to fund part of its acquisition of Cook Pharmica

BRIEF-Catalent files for common stock offering of upto $250 million

* Catalent Inc - files for common stock offering of upto $250.0 million- SEC Filing Source text:(http://bit.ly/2xGCzV4) Further company coverage:

Catalent bolsters biopharma business with Cook Pharmica buy

U.S. drug contract manufacturer Catalent Inc <CTLT.N> agreed to buy Cook Pharmica LLC for $950 million in cash as the company doubles down on its fast-growing business of supplying biologics to drugmakers.

Catalent to buy Cook Pharmica for $950 mln

U.S. drug delivery technology company Catalent Inc said on Tuesday it would buy privately held Cook Pharmica LLC for $950 million in cash.

BRIEF-Catalent Inc to acquire Cook Pharmica for $950 million

* $750 million of deal value to be paid at closing and balance to be paid in equal installments

BRIEF-Catalent Q4 adjusted non-GAAP earnings per share $0.65

* Catalent, Inc. Reports fourth quarter and full year 2017 results

BRIEF-Catalent reports Q3 earnings per share $0.21

* Catalent, Inc. reports third quarter fiscal year 2017 results

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up